ERBB2 and breast cancer: After an in-depth characterization of the resulting hybrid niosomes (referred to as siRNA/FexOy/NIO), the combinational therapy efficacy of the hybrid niosomes together with the anti-tumor drugs trastuzumab and erlotinib was investigated using hormone receptor- and HER2-positive BT-474 breast cancer cells.